Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1969 3
1973 1
1974 1
1977 1
1981 1
1982 1
1983 1
1991 2
1992 2
1993 3
1994 1
1995 1
1997 1
1998 2
1999 1
2000 1
2002 1
2006 1
2008 1
2009 2
2010 1
2011 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Laparoscopic closure of perforated duodenal ulcer.
Sigman HH, Garzon J, Marelli D. Sigman HH, et al. J Laparoendosc Surg. 1992 Dec;2(6):325-7; discussion 329-30. doi: 10.1089/lps.1992.2.325. J Laparoendosc Surg. 1992. PMID: 1489998
CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.
Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B. Perea SE, et al. Among authors: sigman h. Mol Cell Biochem. 2011 Oct;356(1-2):45-50. doi: 10.1007/s11010-011-0950-y. Epub 2011 Jul 7. Mol Cell Biochem. 2011. PMID: 21735096 Clinical Trial.
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, López-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, López E, Falcón V, Hernández I, Solares M, Santana A, Díaz A, Ramos T, López C, Ariosa J, González LJ, Garay H, Gómez D, Gómez R, Alonso DF, Sigman H, Herrera L, Acevedo B. Perea SE, et al. Among authors: sigman h. Mol Cell Biochem. 2008 Sep;316(1-2):163-7. doi: 10.1007/s11010-008-9814-5. Epub 2008 Jun 25. Mol Cell Biochem. 2008. PMID: 18575815 Clinical Trial.
Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.
Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, López-Saura P. Solares AM, et al. Among authors: sigman h. BMC Cancer. 2009 May 13;9:146. doi: 10.1186/1471-2407-9-146. BMC Cancer. 2009. PMID: 19439079 Free PMC article. Clinical Trial.
Pharmacology of gentamicin in the biliary tract of humans.
Mendelson J, Portnoy J, Sigman H. Mendelson J, et al. Among authors: sigman h. Antimicrob Agents Chemother. 1973 Nov;4(5):538-41. doi: 10.1128/AAC.4.5.538. Antimicrob Agents Chemother. 1973. PMID: 4791487 Free PMC article.
31 results